0001193125-26-182254.txt : 20260427 0001193125-26-182254.hdr.sgml : 20260427 20260427163850 ACCESSION NUMBER: 0001193125-26-182254 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20260427 FILED AS OF DATE: 20260427 DATE AS OF CHANGE: 20260427 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Clark David Michael CENTRAL INDEX KEY: 0001755662 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 26901625 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS, INC. CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 47 HULFISH STREET CITY: PRINCETON STATE: NJ ZIP: 08542 FORMER COMPANY: FORMER CONFORMED NAME: AMICUS THERAPEUTICS INC DATE OF NAME CHANGE: 20020729 4 1 ownership.xml 4 X0609 4 2026-04-27 true 0001178879 AMICUS THERAPEUTICS, INC. FOLD 0001755662 Clark David Michael false 47 HULFISH STREET PRINCETON NJ 08542 false true false false Chief People Officer false Common Stock 2026-04-27 4 D false 221811 14.50 D 0 D Stock Options (right to buy) 12.84 2026-04-27 4 D false 84842 D 2028-10-09 Common Stock 84842 0 D Stock Options (right to buy) 10.04 2026-04-27 4 D false 77134 D 2029-01-02 Common Stock 77134 0 D Stock Options (right to buy) 9.55 2026-04-27 4 D false 91439 D 2030-01-02 Common Stock 91439 0 D Stock Options (right to buy) 12.11 2026-04-27 4 D false 108266 D 2032-01-14 Common Stock 108266 0 D Stock Options (right to buy) 11.93 2026-04-27 4 D false 105388 D 2033-01-03 Common Stock 105388 0 D Stock Options (right to buy) 14.24 2026-04-27 4 D false 83221 D 2034-01-02 Common Stock 83221 0 D Stock Options (right to buy) 9.41 2026-04-27 4 D false 125430 D 2035-01-03 Common Stock 125430 0 D The reported securities were disposed of in connection with consummation of the acquisition of the Issuer by BioMarin Pharmaceutical Inc. (the "Merger"), which included 130,942 shares of Common Stock and 90,869 restricted stock units (which vested in full in connection with consummation of the Merger). In connection with consummation of the Merger, each reported stock option ("Option") was cancelled and converted into the right to receive a cash payment equal to (a) the excess of (i) $14.50 per share over (ii) the exercise price payable per share, multiplied by (b) the total number of shares subject to such Option. Each Option was fully vested. Each Option vested in full in connection with consummation of the Merger. /s/ Christian Formica, Attorney-in-Fact 2026-04-27